Scores for sepsis detection and risk stratification - construction of a novel score using a statistical approach and validation of RETTS.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 22 11 2019
accepted: 01 02 2020
entrez: 21 2 2020
pubmed: 23 2 2020
medline: 10 5 2020
Statut: epublish

Résumé

To allow early identification of patients at risk of sepsis in the emergency department (ED), a variety of risk stratification scores and/or triage systems are used. The first aim of this study was to develop a risk stratification score for sepsis based upon vital signs and biomarkers using a statistical approach. Second, we aimed to validate the Rapid Emergency Triage and Treatment System (RETTS) for sepsis. RETTS combines vital signs with symptoms for risk stratification. We retrospectively analysed data from two prospective, observational, multicentre cohorts of patients from studies of biomarkers in ED. A candidate risk stratification score called Sepsis Heparin-binding protein-based Early Warning Score (SHEWS) was constructed using the Least Absolute Shrinkage and Selector Operator (LASSO) method. SHEWS and RETTS were compared to National Early Warning Score 2 (NEWS2) for infection-related organ dysfunction, intensive care or death within the first 72h after admission (i.e. sepsis). 506 patients with a diagnosed infection constituted cohort A, in which SHEWS was derived and RETTS was validated. 435 patients constituted cohort B of whom 184 had a diagnosed infection where both scores were validated. In both cohorts (A and B), AUC for infection-related organ dysfunction, intensive care or death was higher for NEWS2, 0.80 (95% CI 0.76-0.84) and 0.69 (95% CI 0.63-0.74), than RETTS, 0.74 (95% CI 0.70-0.79) and 0.55 (95% CI 0.49-0.60), p = 0.05 and p <0.01, respectively. SHEWS had the highest AUC, 0.73 (95% CI 0.68-0.79) p = 0.32 in cohort B. Even with a statistical approach, we could not construct better risk stratification scores for sepsis than NEWS2. RETTS was inferior to NEWS2 for screening for sepsis.

Sections du résumé

BACKGROUND
To allow early identification of patients at risk of sepsis in the emergency department (ED), a variety of risk stratification scores and/or triage systems are used. The first aim of this study was to develop a risk stratification score for sepsis based upon vital signs and biomarkers using a statistical approach. Second, we aimed to validate the Rapid Emergency Triage and Treatment System (RETTS) for sepsis. RETTS combines vital signs with symptoms for risk stratification.
METHODS
We retrospectively analysed data from two prospective, observational, multicentre cohorts of patients from studies of biomarkers in ED. A candidate risk stratification score called Sepsis Heparin-binding protein-based Early Warning Score (SHEWS) was constructed using the Least Absolute Shrinkage and Selector Operator (LASSO) method. SHEWS and RETTS were compared to National Early Warning Score 2 (NEWS2) for infection-related organ dysfunction, intensive care or death within the first 72h after admission (i.e. sepsis).
RESULTS
506 patients with a diagnosed infection constituted cohort A, in which SHEWS was derived and RETTS was validated. 435 patients constituted cohort B of whom 184 had a diagnosed infection where both scores were validated. In both cohorts (A and B), AUC for infection-related organ dysfunction, intensive care or death was higher for NEWS2, 0.80 (95% CI 0.76-0.84) and 0.69 (95% CI 0.63-0.74), than RETTS, 0.74 (95% CI 0.70-0.79) and 0.55 (95% CI 0.49-0.60), p = 0.05 and p <0.01, respectively. SHEWS had the highest AUC, 0.73 (95% CI 0.68-0.79) p = 0.32 in cohort B.
CONCLUSIONS
Even with a statistical approach, we could not construct better risk stratification scores for sepsis than NEWS2. RETTS was inferior to NEWS2 for screening for sepsis.

Identifiants

pubmed: 32078640
doi: 10.1371/journal.pone.0229210
pii: PONE-D-19-32440
pmc: PMC7032705
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0229210

Déclaration de conflit d'intérêts

Bertil Christensson, Per.Åkesson, and Adam Linder are listed as inventors on a patent on the use of HBP as a diagnostic tool in sepsis filed by Hansa Medical AB WO2008151808A1. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors have declared no relevant conflicts of interest.

Références

Clin Infect Dis. 2009 Oct 1;49(7):1044-50
pubmed: 19725785
JAMA. 2010 Aug 18;304(7):747-54
pubmed: 20716737
Crit Care Med. 2015 Jan;43(1):13-21
pubmed: 25251760
Scand J Trauma Resusc Emerg Med. 2018 Oct 19;26(1):88
pubmed: 30340502
Crit Care Med. 2015 Nov;43(11):2378-86
pubmed: 26468696
J Appl Physiol Respir Environ Exerc Physiol. 1979 Mar;46(3):599-602
pubmed: 35496
Crit Care. 2019 Feb 21;23(1):60
pubmed: 30791952
Sci Transl Med. 2015 Aug 5;7(299):299ra122
pubmed: 26246167
N Engl J Med. 2015 Apr 23;372(17):1629-38
pubmed: 25776936
Shock. 2019 Dec;52(6):e135-e145
pubmed: 30807529
J Clin Med. 2019 Jul 29;8(8):
pubmed: 31362432
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Nat Med. 2001 Oct;7(10):1123-7
pubmed: 11590435
J Emerg Med. 2011 Jun;40(6):623-8
pubmed: 18930373
Eur J Emerg Med. 2015 Oct;22(5):363-5
pubmed: 25485968
Ann Emerg Med. 2019 Apr;73(4):334-344
pubmed: 30661855
PLoS Pathog. 2008 Sep 12;4(9):e1000149
pubmed: 18787689
Int J Med Inform. 2017 Jul;103:1-6
pubmed: 28550994
J Immunol. 2005 May 15;174(10):6399-405
pubmed: 15879141
Infect Dis (Lond). 2017 Jul;49(7):507-513
pubmed: 28276800
Intensive Care Med. 2003 Apr;29(4):530-8
pubmed: 12664219
Crit Care Med. 2006 Jun;34(6):1589-96
pubmed: 16625125
Scand J Trauma Resusc Emerg Med. 2017 Jun 9;25(1):56
pubmed: 28599661
Cell. 2004 Feb 6;116(3):367-79
pubmed: 15016372
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
J Am Geriatr Soc. 2017 Aug;65(8):1802-1809
pubmed: 28440855

Auteurs

Lisa Mellhammar (L)

Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.

Adam Linder (A)

Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.

Jonas Tverring (J)

Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.

Bertil Christensson (B)

Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.

John H Boyd (JH)

Division of Critical Care Medicine, Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

Per Åkesson (P)

Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.

Fredrik Kahn (F)

Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH